Cover Image
市場調查報告書

支氣管炎:開發平台分析

Bronchitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232856
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
支氣管炎:開發平台分析 Bronchitis - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 59 Pages
簡介

支氣管炎是指支氣管內側發炎的狀態。支氣管的作用是將空氣運送到肺部。症狀有含痰的咳嗽、有時痰中也會帶血。此外激烈或中等程度的運動後會呼吸困難,更會頻繁感染讓症狀惡化的呼吸系統感染疾病、喘鳴和疲勞、腳踝疼痛、頭痛等。

本報告提供支氣管炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍

支氣管炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • Boehringer Ingelheim GmbH
  • DBV Technologies S.A.
  • Hyundai Pharmaceutical Co., Ltd.
  • Invion Limited
  • Mucosis B.V.
  • Orbis Biosciences, Inc.
  • Recipharm AB

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BI-113608
  • erdosteine
  • HOB-051
  • nadolol
  • nitric oxide
  • prednisone
  • RS病毒疫苗
  • SynGEM

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8502IDB

Summary

Global Markets Direct's, 'Bronchitis - Pipeline Review, H2 2016', provides an overview of the Bronchitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bronchitis
  • The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects
  • The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bronchitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bronchitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bronchitis Overview
  • Therapeutics Development
    • Pipeline Products for Bronchitis - Overview
  • Bronchitis - Therapeutics under Development by Companies
  • Bronchitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bronchitis - Products under Development by Companies
  • Bronchitis - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • DBV Technologies S.A.
    • F. Hoffmann-La Roche Ltd.
    • Hyundai Pharmaceutical Co., Ltd.
    • Invion Limited
    • Kyorin Pharmaceutical Co., Ltd.
    • Mucosis B.V.
    • Orbis Biosciences Inc
    • Recipharm AB
  • Bronchitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alteplase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-9668 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erdosteine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRPAM-1977X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nadolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitric oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prednisone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SynGEM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bronchitis - Dormant Projects
  • Bronchitis - Discontinued Products
  • Bronchitis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical
      • Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical
      • Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation
      • Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
      • Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings
      • Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants
      • Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
      • Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bronchitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Bronchitis - Pipeline by AstraZeneca Plc, H2 2016
  • Bronchitis - Pipeline by DBV Technologies S.A., H2 2016
  • Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Bronchitis - Pipeline by Invion Limited, H2 2016
  • Bronchitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Bronchitis - Pipeline by Mucosis B.V., H2 2016
  • Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2016
  • Bronchitis - Pipeline by Recipharm AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bronchitis - Dormant Projects, H2 2016
  • Bronchitis - Dormant Projects (Contd..1), H2 2016
  • Bronchitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bronchitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top